These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

704 related items for PubMed ID: 15831602

  • 21. Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction.
    Sander GE, McKinnie JJ, Greenberg SS, Giles TD.
    Prog Cardiovasc Dis; 1999; 41(4):265-300. PubMed ID: 10362349
    [Abstract] [Full Text] [Related]

  • 22. [Heart failure after acute myocardial infarct. Early aldosterone blockade increases survival rate].
    MMW Fortschr Med; 2005 Jul 07; 147(27-28):44. PubMed ID: 16041942
    [No Abstract] [Full Text] [Related]

  • 23. Pharmacotherapy for heart failure with left ventricular dysfunction: beyond angiotensin-converting enzyme inhibitors and beta-blockers.
    Norgard NB, Stark JE.
    Pharmacotherapy; 2008 Jul 07; 28(7):920-31. PubMed ID: 18576907
    [Abstract] [Full Text] [Related]

  • 24. Role of aldosterone blockade for treatment of heart failure and post-acute myocardial infarction.
    Greenberg B, Zannad F, Pitt B.
    Am J Cardiol; 2006 May 22; 97(10A):34F-40F. PubMed ID: 16698333
    [Abstract] [Full Text] [Related]

  • 25. [Therapeutic management of heart failure and left ventricular dysfunction following acute myocardial infarction in French intensive care units].
    Cambou JP, Vicaut E, Papadopoulos-Degrandsart A, Danchin N.
    Ann Cardiol Angeiol (Paris); 2007 Jan 22; 56(1):36-41. PubMed ID: 17343037
    [Abstract] [Full Text] [Related]

  • 26. What can we learn from Europe?
    Swedberg K.
    Heart; 2005 May 22; 91 Suppl 2(Suppl 2):ii21-3; discussion ii31, ii43-8. PubMed ID: 15831604
    [Abstract] [Full Text] [Related]

  • 27. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM, Sanoski CA, Spinler SA.
    Pharmacotherapy; 2009 Jan 22; 29(1):31-48. PubMed ID: 19113795
    [Abstract] [Full Text] [Related]

  • 28. Ventricular remodeling and its prevention in the treatment of heart failure.
    Patten RD, Udelson JE, Konstam MA.
    Curr Opin Cardiol; 1998 May 22; 13(3):162-7. PubMed ID: 9649938
    [Abstract] [Full Text] [Related]

  • 29. Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function.
    Suşan M, Petrescu L, Riviş AI, Suşan RM, Burghină D, Dan R, Cozma D, Drăgulescu SI.
    Rom J Intern Med; 2005 May 22; 43(3-4):187-98. PubMed ID: 16812979
    [Abstract] [Full Text] [Related]

  • 30. Combining neuroendocrine inhibitors in heart failure: reflections on safety and efficacy.
    Jneid H, Moukarbel GV, Dawson B, Hajjar RJ, Francis GS.
    Am J Med; 2007 Dec 22; 120(12):1090.e1-8. PubMed ID: 18060931
    [Abstract] [Full Text] [Related]

  • 31. [Trandolapril in the prevention of the sequelae of left ventricular systolic dysfunction after acute myocardial infarct].
    Buksa M.
    Med Arh; 2000 Dec 22; 54(2):103-6. PubMed ID: 10934839
    [Abstract] [Full Text] [Related]

  • 32. Drug therapy for chronic heart failure due to left ventricular systolic dysfunction: a review. III. Angiotensin-converting enzyme inhibitors.
    Ascenção R, Fortuna P, Reis I, Carneiro AV.
    Rev Port Cardiol; 2008 Sep 22; 27(9):1169-87. PubMed ID: 19044179
    [Abstract] [Full Text] [Related]

  • 33. Angiotensin-converting enzyme inhibitors in left ventricular dysfunction.
    Linn WD.
    Pharmacotherapy; 1996 Sep 22; 16(2 Pt 2):50S-58S. PubMed ID: 8668606
    [Abstract] [Full Text] [Related]

  • 34. Angiotensin-converting enzyme inhibitors, beta-blockers, and mortality in systolic heart failure.
    Thornton PL, Ahmed A.
    J Am Coll Cardiol; 2004 Apr 07; 43(7):1333; author reply 1333-4. PubMed ID: 15063454
    [No Abstract] [Full Text] [Related]

  • 35. Switching to evidence-based once-daily beta-blockers for improved adherence to medication across the continuum of post-myocardial infarction left ventricular dysfunction and heart failure.
    Abraham WT.
    Congest Heart Fail; 2008 Apr 07; 14(5):272-80. PubMed ID: 18983291
    [Abstract] [Full Text] [Related]

  • 36. The pharmacological treatment of heart failure: are we looking at the sunset of the neurohormonal hypothesis.
    Porcu M.
    Ital Heart J; 2002 Jul 07; 3(7):437-8. PubMed ID: 12189976
    [No Abstract] [Full Text] [Related]

  • 37. Applying standard therapies to new targets: the use of ACE inhibitors and B-blockers for heart failure in adults with congenital heart disease.
    Vonder Muhll I, Liu P, Webb G.
    Int J Cardiol; 2004 Dec 07; 97 Suppl 1():25-33. PubMed ID: 15590076
    [Abstract] [Full Text] [Related]

  • 38. Use of beta-blockers during and after myocardial infarction.
    Aronow WS.
    Compr Ther; 1998 Dec 07; 24(6-7):327-31. PubMed ID: 9669097
    [Abstract] [Full Text] [Related]

  • 39. Sudden cardiac death after heart failure; symptomatic versus disease treatment? An editorial comment.
    Buckberg GD, RESTORE team.
    Heart Fail Rev; 2004 Oct 07; 9(4):347-51. PubMed ID: 15886980
    [No Abstract] [Full Text] [Related]

  • 40. [Ambulatory management of patients after myocardial infarction].
    Bloch A.
    Rev Med Suisse Romande; 2000 Feb 07; 120(2):159-66. PubMed ID: 10748703
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 36.